I’ve been teaching 505(b)(2) drug development for almost 3 years now at US, EU and Middle Eastern venues. I was invited to give a short course at the upcoming Drug Re-Positioning Summit in Philadelpia on the morning of October 10 (conference goes thru the 11th).
How to take a day and a half topic and shorten [...]
Search
About
You are currently browsing the Drug Kennel weblog archives for the day Monday, September 17th, 2007.
Longer entries are truncated. Click the headline of an entry to read it in its entirety.
Latest
- Failed 505(b)(2)?: Vivus’ Qnexa
- Will We Have Generic User Fees? Public Meeting To Be Held.
- Lannett’s Morphine Sulfate Oral Solution: 505(b)(2) or 505j?
- Generic Lovenox – 505j or 505(b)(2)
- New User Fees for 2011
- Still submitting paper ANDA applications?
- What should a license cost?
- Avandia: Who Won?
- Advisory Committee Meeting: Rosiglitazone
- The skinny on a potential new treatment of obesity